Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

ResMed Inc. RMD

Healthcare — Medical Instruments & Supplies
S&P 500 Member Dividend Champion (5y) Cash Flow Champion (3y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
23.39
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 5 4 4 4 3 3 1 1 1 2 2
Insider Ownership
1.82%

Capital & Financial Ratios

Market Cap
32,950.00
Revenue
5,653.44
Net Income
1,523.29
Free Cash Flow
1,628.66
Net Debt
(1,069.82)
Current Ratio
3.10
Debt/Equity
0.06
P/E ratio
21.51
P/S ratio
5.79
P/B ratio
4.97
Past 5Y EPS Growth
19.83%
This Y EPS Growth
8.28%
Next Y EPS Growth
10.01%
Next 5Y EPS Growth
9.26%
in millions of $

Dividends

Payout Ratio
0.29
Annual Dividend Rate
1.92
Annual Dividend Yield
1.06%
total individual payouts
2029 ‡‡‡‡‡
2028 ‡‡‡‡‡
2027 ‡‡‡‡
2026 2.43
—
—
—
2025 2.26
—
—
—
—
2024 2.02
—
—
—
—
2023 1.84
—
—
—
—
2022 1.72
—
—
—
—
2021 1.62
—
—
—
—
2020 1.56
—
—
—
—
2019 1.52
—
—
—
—
2018 1.44
—
—
—
—
2017 1.36
—
—
—
—
2016 1.26
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 2026
Cash 227.89 238.36 1,209.45 1,469.23
Receivables 704.91 837.28 939.49 1,036.23
Inventory 998.01 822.25 927.71 945.81
Other 405.00 — — 457.39
2,367.83 2,357.72 3,505.61 4,324.74
2023 2024 2025 2026
Payables 150.76 237.73 278.16 308.92
ST’ Debt 32.00 — — —
Other 504.00 — — 41.16
758.53 910.66 1,019.12 1,395.11
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Sep Dec Mar Jun Year
’26 — — — —
—
’26 1,335.58 1,422.81 1,431.41 1,463.65
5,653.44
’25 1,224.51 1,282.09 1,291.74 1,347.99
5,146.33
’24 1,102.32 1,162.80 1,196.98 1,223.20
4,685.30
’23 950.29 1,033.74 1,116.90 1,122.06
4,222.99
’22 904.02 894.87 864.50 914.74
3,578.13
’21 751.94 800.01 768.77 876.10
3,196.83
in millions of $

Operating Cash Flow

Sep Dec Mar Jun Year
’26 — — — —
—
’26 457.32 339.75 554.13 454.63
1,805.83
’25 325.54 308.62 578.66 538.77
1,751.59
’24 286.28 272.83 402.03 440.11
1,401.26
’23 44.66 128.64 282.57 237.44
693.30
’22 (65.66) 219.88 117.44 79.49
351.15
’21 144.00 169.92 196.28 226.53
736.72
in millions of $

Free Cash Flow

Sep Dec Mar Jun Year
’26 — — — —
—
’26 411.54 305.19 514.54 397.38
1,628.66
’25 305.93 285.15 554.87 504.99
1,650.95
’24 245.42 248.27 378.92 413.79
1,286.40
’23 12.29 96.97 251.34 198.70
559.30
’22 (97.45) 180.19 65.28 47.09
195.11
’21 125.26 131.84 167.13 195.65
619.89
in millions of $

EPS

Sep Dec Mar Jun Year
’26 — — — —
—
’26 2.37 2.68 2.74 2.64
10.43
’25 2.11 2.34 2.48 2.58
9.51
’24 1.49 1.42 2.04 1.98
6.92
’23 1.43 1.53 1.58 1.56
6.09
’22 1.39 1.37 1.22 1.33
5.30
’21 1.22 1.23 (0.54) 1.33
3.24

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

2.1
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 189.40 132.24 164.12 199.92 180.27 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 262.38 243.52 260.49 293.81 277.67 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8,160 10,140 9,980 10,600 11,370 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.44 0.42 0.47 0.49 0.50 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,578.13 4,222.99 4,685.30 5,146.33 5,653.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.57% 55.78% 56.67% 59.36% 61.06% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 960.48 1,101.66 1,264.80 1,677.57 1,919.42 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.84% 26.09% 27.00% 32.60% 33.95% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 779.44 897.56 1,020.95 1,400.72 1,523.29 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 193.84 197.56 216.21 235.81 244.15 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.50 28.77 31.87 35.08 38.85 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 5.34 6.12 6.94 9.55 10.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.40 4.72 9.53 11.94 12.41 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.07) (0.91) (0.78) (0.69) (1.22) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.34 3.81 8.75 11.25 11.19 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.01 28.14 33.08 40.68 45.25 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 146.07 146.77 147.02 146.72 145.52 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.33 35.76 26.94 27.02 18.63 ‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.56 7.59 5.87 7.36 5.02 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.11 7.76 5.65 6.34 4.31 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.70 7.89 5.97 7.25 4.83 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 159.62 59.55 21.75 22.61 16.78 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 351.15 693.30 1,401.26 1,751.59 1,805.83 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (156.04) (134.00) (114.86) (100.64) (177.17) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 195.11 559.30 1,286.40 1,650.95 1,628.66 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,242.18 1,609.30 1,447.06 2,486.49 2,929.63 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 797.33 1,463.23 697.31 658.39 399.42 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 523.62 1,235.34 458.95 (551.06) (1,069.82) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,360.75 4,129.90 4,864.04 5,967.86 6,585.39 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.87% 15.15% 14.99% 18.62% 17.77% ‡‡‡‡‡ — —
ROA
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.09% 13.19% 15.50% 19.45% 21.38% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.96% 23.96% 22.70% 25.86% 24.27% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

ResMed Inc. (RMD), a powerhouse in sleep apnea devices and digital health, has delivered impressive growth amid rising OSA cases from obesity and aging populations, with revenue more than doubling to $4.69 billion over the past decade at a 12% CAGR—outpacing medtech peers. Strategic moves like the Brightree acquisition have boosted SaaS revenue, while efficiency shines through revenue per employee jumping to $469,000 and gross margins rebounding to 59%. Despite GLP-1 drug headwinds, analysts forecast 10% revenue growth to $5.65 billion by 2026, fueled by strong U.S. market share and international expansion.

Profitability is surging, with EBT margins hitting 27% in 2024 and projected at 33% in 2025, driving net income up 37% YoY and elite ROE averaging 22%. Free cash flow per share has soared 156% to $8.75, flipping the balance sheet to a net cash position, supporting dividends and R&D without excessive debt. Stock performance reflects this, with highs up 266% over the decade and reduced volatility, though insider sells (likely pre-scheduled) warrant watching.

Valuation looks compelling at 24x forward P/E and 6x EV/Sales—below historical peaks and medtech peers—implying 24% upside per analysts, with potential for re-rating on SaaS traction and demographic tailwinds. As a defensive growth play, ResMed’s fundamentals scream opportunity in uncertain markets. Dive into the full analysis for charts, forecasts, and risks like reimbursement pressures.

Read full commentary →

ResMed Inc. (RMD) Latest News

News by impact score

Fine-tune

19 Sep

3 , 4:18 AM
ResMed Inc. leverages its leadership in sleep apnea to sustain growth despite rising competitive pressures. ResMed's established sleep apnea position sustains growth even as competitors intensify.

15 Sep

3 , 4:07 PM
ResMed Inc. receives analyst upgrade with experts citing favorable views on the sleep device maker's outlook and potential. Analyst upgrade may lift near-term investor sentiment and share price without altering core business trajectory.

3 www.barchart.com, 3:57 PM
Analyst upgraded ResMed Inc. (RMD) stock and outlined supporting reasons for the positive rating. Analyst upgrade may moderately influence short-term market sentiment and share price without altering ResMed's core trajectory.

3 , 1:11 PM
Rising costs are pressuring margins at ResMed Inc. and may alter the investment case for the stock. Margin pressure from rising costs can affect ResMed financial performance and stock trajectory.

1 Sep

3 , 8:30 AM
Frazier Healthcare Partners acquires MatrixCare and appoints Jonathan Lujan as CEO. Divestiture of MatrixCare unit allows ResMed to refocus resources on core sleep apnea and respiratory products.

17 Aug

3 , 3:28 PM
ResMed’s sleep business continues to expand while one product faces setbacks. Core sleep segment growth likely supports performance while single-product issues limit broader effects.

14 Aug

4 transcript www.fool.com, 11:13 AM
ResMed Inc. held its Q4 2026 earnings call, covering quarterly financial results, operational updates, and forward guidance for the sleep apnea and respiratory device maker. Earnings call delivers financial results, guidance, and strategic commentary that typically move RMD shares and shape near-term valuation.

12 Aug

3 , 6:12 AM
ResMed (RMD) stock may be 31% undervalued after a soft FY27 outlook. Soft FY27 outlook points to moderate pressure on future growth and market sentiment offset by valuation upside.

11 Aug

3 , 10:33 PM
ResMed's investment case faces potential shifts from recall-damaged outlook and larger dividend payouts. Recall issues and dividend hikes may moderately affect ResMed financials and investor views without fully redefining trajectory.

10 Aug

4 www.medicaldevice-network.com, 7:08 AM
ResMed Inc. stock drops 7% after the company issues a soft FY27 outlook. Soft FY27 guidance directly triggers a 7% stock decline and signals material pressure on future performance expectations.

3 , 1:33 AM
ResMed reports Q2 margin pressures weighing on results even as product momentum and portfolio shifts continue. Q2 margin pressures alongside product momentum indicate limited overall effects on ResMed trajectory.

9 Aug

4 transcript www.marketbeat.com, 12:03 AM
ResMed Inc. (RMD) Q4 earnings call covered financial results, operational updates, and forward guidance. Earnings call details directly shape near-term stock movement and strategic outlook for RMD.

7 Aug

4 transcript , 1:12 AM
ResMed Inc reported strong revenue growth in Q4 2026 alongside strategic initiatives during its earnings call. Strong revenue growth and strategic moves signal significant positive effects on future performance and investor sentiment.

3 investorshub.advfn.com, 8:41 AM
ResMed shares declined after the company missed revenue expectations and issued a conservative 2027 outlook. Revenue miss combined with cautious 2027 guidance points to potential growth constraints affecting near-term performance.

6 Aug

4 , 4:05 PM
ResMed Inc. announced financial results for the fourth quarter of fiscal year 2026. Quarterly earnings releases directly shape investor views and near-term stock movements for the company.

3 , 5:40 PM
ResMed Inc. exceeded estimates for Q4 earnings and revenues. Q4 earnings and revenue beat offers moderate positive signal for near-term financials and sentiment without major strategic or competitive shifts.

21 Jul

3 , 1:05 PM
UBS sees strong earnings growth for ResMed despite ventilator issues potentially clouding FY27 outlook. Ventilator issue may weigh on FY27 while earnings growth remains strong.

10 Jul

4 , 7:14 AM
ResMed Inc. sells MatrixCare to refocus on sleep and respiratory health. Divestiture of MatrixCare represents a major strategic refocus that reallocates resources to core sleep and respiratory operations.

3 , 12:51 PM
ResMed Inc. divests MatrixCare business to sharpen focus on connected care. Divestiture enables sharpened strategic focus on connected care.

8 Jul

4 www.medicaldevice-network.com, 9:53 AM
ResMed sells software business for $490 million to sharpen focus on sleep care. Divestiture of $490m software unit enables strategic refocus on sleep care core business.

3 www.medtechdive.com, 7:28 AM
ResMed Inc. agreed to sell its MatrixCare business to a private equity firm for $490 million. Divestiture injects $490 million cash while removing a non-core software unit and allowing sharper focus on medical devices.

7 Jul

3 , 6:07 PM
ResMed Inc. agrees to sell its MatrixCare software business for $490 million. Sale of non-core MatrixCare unit injects $490 million cash while refocusing ResMed on primary medical device operations without fundamentally shifting overall trajectory.

3 , 5:06 PM
Frazier Healthcare Partners has signed a definitive agreement to acquire MatrixCare. MatrixCare divestiture alters RMD's post-acute care software exposure and may affect near-term revenue mix.

3 , 4:30 PM
ResMed Inc. announces agreement to sell its MatrixCare business. Divestiture of MatrixCare shifts ResMed focus to core respiratory operations and alters financial profile.

25 Jun

3 Insider Monkey, 8:40 AM
ResMed Inc. (RMD) stock faces questions on long-term winner status amid ongoing OSA market expansion. OSA market expansion may moderately influence ResMed financial performance and positioning without fundamentally altering trajectory.

5 Jun

3 Insider Monkey, 5:24 PM
ResMed Inc. acquires Noctrix Health to expand sleep disorder portfolio. Acquisition adds to ResMed sleep disorder offerings with potential moderate effect on product range.

4 Jun

3 www.medicaldevice-network.com, 7:17 AM
ResMed Inc. completed the $340 million acquisition of Noctrix Health. $340 million acquisition adds Noctrix Health capabilities with moderate effect on ResMed operations and positioning.

3 Jun

3 Simply Wall St., 8:14 AM
ResMed Inc. (RMD) shares fell 25%, raising questions on whether the stock requires reassessment. 25% share price drop signals potential shifts in investor perception and company valuation.

3 GlobeNewswire, 7:40 AM
ResMed acquires Noctrix Health for $340 million, marking Angelini Ventures' first portfolio company exit. The $340 million acquisition adds specialized health technology to ResMed's portfolio at moderate scale relative to company size.

2 Jun

4 www.medtechdive.com, 2:30 AM
ResMed completes $340M Noctrix takeover. $340M Noctrix acquisition marks major strategic expansion in ResMed core sleep market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us